Intrexon Corporation (NYSE: XON) and Immunomedics (NASDAQ:IMMU) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.
Valuation and Earnings
This table compares Intrexon Corporation and Immunomedics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Intrexon Corporation||$202.92 million||10.76||-$99.62 million||($1.03)||-17.58|
|Immunomedics||$3.09 million||417.39||-$71.33 million||($1.43)||-8.10|
Immunomedics has higher revenue, but lower earnings than Intrexon Corporation. Intrexon Corporation is trading at a lower price-to-earnings ratio than Immunomedics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Intrexon Corporation has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Immunomedics has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.
This is a summary of recent ratings for Intrexon Corporation and Immunomedics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Intrexon Corporation presently has a consensus target price of $43.20, indicating a potential upside of 138.54%. Immunomedics has a consensus target price of $15.50, indicating a potential upside of 33.74%. Given Intrexon Corporation’s higher probable upside, analysts clearly believe Intrexon Corporation is more favorable than Immunomedics.
Institutional & Insider Ownership
82.1% of Intrexon Corporation shares are owned by institutional investors. Comparatively, 57.4% of Immunomedics shares are owned by institutional investors. 55.1% of Intrexon Corporation shares are owned by insiders. Comparatively, 6.6% of Immunomedics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Intrexon Corporation and Immunomedics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Intrexon Corporation beats Immunomedics on 8 of the 13 factors compared between the two stocks.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
Immunomedics Company Profile
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.